ARTIST Registry
Acute Orthopedic Trauma
Key Facts
About Artoss
Artoss is a commercial-stage orthobiologics company with its core product, NanoBone, already approved and used in over 100,000 surgical cases in the U.S. and EU. The company's technology is centered on a unique nanocrystalline hydroxyapatite embedded in an amorphous silica gel matrix (ASG), which is rapidly replaced by the patient's own organic bone matrix. Led by a seasoned executive team with deep experience in medical device sales and orthobiologics, Artoss is targeting the large and growing bone graft substitute market by positioning NanoBone as a cost-effective, easy-to-use, and clinically effective alternative to autograft and more expensive biologics. The company is actively gathering real-world clinical data through several patient registries to further validate and expand the use of its product.
View full company profile